DOCSLIB.ORG

(Olaratumab) for Soft Tissue Sarcoma By: Majd Abedrabbo, Pharmd Candidate 2018 Fairleigh Dickinson University School of Pharmacy May 3, 2017

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(Olaratumab) for Soft Tissue Sarcoma By: Majd Abedrabbo, Pharmd Candidate 2018 Fairleigh Dickinson University School of Pharmacy May 3, 2017 Drug Comparison: LartruvoTM (Olaratumab) for Soft Tissue Sarcoma By: Majd Abedrabbo, PharmD Candidate 2018 Fairleigh Dickinson University School of Pharmacy May 3, 2017 Introduction Soft Tissue Sarcoma (STS) is a rare type of cancer with multiple treatment options. There are approximately 12,390 new cases of STS diagnosed and 4,990 Americans are estimated to die each year in the United States. The standard of care for patients with metastatic STS is treatment with doxorubicin, an anthracycline that was approved in 1974 and is associated with significant toxicity, including myelosuppression, the development of secondary cancers, and dose-limiting cardiotoxicity. Other treatment options include targeted therapies, which interfere with mutated or over-active proteins that drive the cancer. In this article, we compare doxorubicin (Adriamycin), the standard of care, chemotherapeutic agent, with Olaratumab (Lartruvo), a new targeted therapy. Background STS is a collection of cancers of tissues that connect and support the body, like fat cells and blood vessels, which are of mesenchymal origin.1 Since sarcomas need not invade the basement membrane, they have a very high metastatic potential, capable of spreading throughout the body with relative ease. Risk factors of STS include specific genetic diseases, radiation treatments for other cancers, and exposure to chemicals.2 Although there are more than 50 types of STS, the most common types in adults are undifferentiated pleomorphic sarcoma, liposarcoma, and leiomyosarcoma.3 The risk and severity of STS depends on the type, which is dependent upon the location, specific cell of origin, stage of differentiation, and mutations. The standard of care for patients with metastatic STS is treatment with doxorubicin, which disrupts topoisomerase II by intercalating into the DNA, preventing DNA replication and transcription, thereby inducing apoptosis.4 It can be used as 1 monotherapy or in combination with other drugs. When used alone, response rates range from 20-30% with a median overall survival of 7.7 to 12 months. Doxorubicin follows a dose response relationship; therefore, response rates increase when given at higher doses.5 A study conducted by the Southwest Oncology Group (SWOG) included 79 patients who were categorized as good risk patients. They were randomly assigned to doxorubicin doses of 45, 60, or 75 mg/m2 and sarcoma response rates were 18, 20, and 37%, respectively.6 The optimal dose response ranges from 75 to 90 mg/m2.5 Olaratumab is a fully human IgG1 monoclonal antibody that binds to PDGFR-α (Platelet Derived Growth Factor Receptor), which is expressed on mesenchymal cells, including sarcomas. It is highly specific in its binding to PDGFR-α, which is a receptor tyrosine kinase that plays a significant role in cell growth, chemotaxis, and cell differentiation. PDGFR-α is located on tumor cells, stromal cells, and sarcomas, and provides signals that drive proliferation of cancer cells and metastases.8 The Food and Drug Administration (FDA) granted the olaratumab fast track designation, breakthrough therapy designation, and priority review status because Phase II trails suggested “evidence indicating substantial improvement in effectiveness in the treatment of a serious or life-threatening disease or condition.”7 On October 16, 2016, the FDA approved olaratumab in combination with doxorubicin for the treatment of STS. A two-part open-label, multicenter, randomized, active-controlled, phase 1b and phase 2 study compared the effectiveness of doxorubicin single agent and combination doxorubicin plus olaratumab in patients with STS that was unresectable, metastatic, or not amendable to radiotherapy. In the phase 2 segment, a total of 133 patients who were not previously treated with an anthracycline were included: ages 22 to 86 years (median 2 58 years), 44% were men, and the population was predominantly Caucasian. Eligible patients were not previously treated with an anthracycline-containing regimen. Olaratumab was administered at 15 mg/kg IV infusion on days 1 and 8 during each 21- day cycle until toxicity was seen or the disease had progressed. Both arms in the study received doxorubicin 75 mg/m2 IV infusion on day 1 during each 21-day cycle for a maximum of eight cycles. Patients treated with olaratumab plus doxorubicin had an overall survival of 26.5 months versus 14.7 months for doxorubicin, alone (p < 0.05).9 In this pivotal study, participants were permitted to receive dexrazoxane (a cardio- protective agent) before administration of doxorubicin in cycles 5 to 8 because doxorubicin has been associated with severe and life-threatening cardiotoxicity. The exact mechanism of cardiotoxicity is controversial, but one main theory relates to the formation of doxorubicin metabolites and iron-related free radicals. This mechanism is supported by evidence that the administration of dexrazoxane, an iron chelator, provides protection from doxorubicin toxicity.10 Cardiotoxicity can occur early (acute) or late (delayed). Acute cardiotoxicity consists of ECG abnormalities and sinus tachycardia. Symptoms of delayed cardiotoxicity can occur after months or even several years following completion of treatment and include tachycardia, dyspnea, and pulmonary edema, all of which indicate the development of irreversible congestive heart failure (CHF). The risk of developing CHF increases with higher doses, but doxorubicin-induced cardiotoxicity can also occur at lower doses in patients with risk factors, including pre- existing heart disease, exposure at an early age, advanced age, and concomitant use of other cardiotoxic agents. The potential damage seen begins at cumulative doses of doxorubicin of more than 300 mg/m2. Other severe adverse reactions caused by 3 doxorubicin are severe myelosuppression, occurrence of secondary leukemia (acute myeloid leukemia or myelodysplastic syndrome), and peripheral neurotoxicity.11 In olaratumab treated patients, adverse reactions that resulted in permanent discontinuation occurred in 8% of patients. The primary cause of discontinuation is infusion-related reactions, which is included as a warning in the label. The most common adverse reactions (> 20%) associated with the drug are nausea, fatigue, musculoskeletal pain, mucositis, alopecia, vomiting, diarrhea, decreased appetite, abdominal pain, neuropathy, and headache. The most common laboratory abnormalities (> 20%) seen with the use of olaratumab are lymphopenia, neutropenia, thrombocytopenia, hyperglycemia, elevated aPTT, hypokalemia, and hypophosphatemia. Although the combination of olaratumab plus doxorubicin increases the risk of gastrointestinal side effects, fatigue, and bone marrow suppression, all chemotherapies used in STS are associated with these toxicities.8 Currently, evidence demonstrates that both doxorubicin and olaratumab are effective for the treatment of STS. It is important to highlight that since olaratumab is indicated in combination with doxorubicin, the increased risk of gastrointestinal effects, fatigue, and bone marrow suppression are more likely attributed to doxorubicin rather than olaratumab. Doxorubicin toxicities are frequently responsible for discontinuation of therapy and dose reductions, both of which reduce the effectiveness of the drug. Olaratumab may be especially helpful in this regard: (1) improved response rates and durations of response could obviate the need for additional courses of therapy; and (2) olaratumab may maintain response rates when dose intensity of doxorubicin needs to be reduced to manage toxicity. 4 The Director of the FDA Office of Hematology and Oncology Products, Richard Pazdur said, “[Olaratumab] is the first new therapy approved by the FDA for the initial treatment of soft tissue sarcoma since doxorubicin’s approval more than 40 years ago”.2 The Hematology-Oncology team lead at Northwestern Medicine, Marco Martino stated, “Approximately 12,310 new cases of STS will be diagnosed in 2016. Despite these setbacks, the 5-year overall survival of STS remains strong at 50% to 60%; thus, there is a significant need for developing treatment options that have good response rates and an acceptable adverse effect profile”.12 Olaratumab provides improved outcomes when used in combination with doxorubicin and may help to lessen the incidence and severity of doxorubicin-related toxicities in the acute and long-term treatment of STS. 5 References 1. Cancer Biology: Discussions of New Developments and Updates. Olaratumab Receives Priority Review for Soft Tissue Sarcoma. http://blogs.shu.edu/cancer/2016/05/11/olaratumab-receives-priority-review-for- soft-tissue-sarcoma/. Accessed April 5, 2017. 2. Fala L. Lartruvo (Olaratumab) a Novel First-Line Treatment Approved for Patients with Advanced Soft-Tissue Sarcoma. Oncology Practice Management. http://oncpracticemanagement.com/issue-archive/2017/january-2017-vol-7-no- 1/lartruvo-olaratumab-a-novel-first-line-treatment-approved-for-patients-with- advanced-soft-tissue-sarcoma/. Published January 2017. Accessed April 22, 2017. 3. American Cancer Society. About Soft Tissue Sarcoma. https://www.cancer.org/cancer/soft-tissue-sarcoma/about/key-statistics.html. Accessed April 8, 2017. 4. Thorn CF, Oshiro C, Marsh S, et al. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenetics and Genomics. 2011;21(7):440-446. doi:10.1097/FPC.0b013e32833ffb56. 5. Purohit S, Bhise R, Appachu S, Lakshmaiah KC, Govindbabu K. Systemic Therapy in Soft Tissue Sarcomas: Past, Present and Future. Indian Journal of Surgical
Load more

Recommended publications
  • HIV MARKET REPORT the State of HIV Treatment, Testing, and Prevention in Low- and Middle-Income Countries
    HIV MARKET REPORT The state of HIV treatment, testing, and prevention in low- and middle-income countries Issue 10, September 2019 Test Treat Stay Smart Right Negative This report was made possible through the generous support of Unitaid, with complementary support from the UK Department for International Development (DFID) and the Bill & Melinda Gates Foundation. Table of Contents Acronyms Used .................................................................................................................................................................... 4 Foreword .............................................................................................................................................................................. 5 2019 Market Report At-a-Glance ..................................................................................................................................... 6 GENERAL TRENDS ........................................................................................................................................................... 7 Figure 1: Major HIV Pricing Updates as of Sep. 2019 .......................................................................................................................... 7 Figure 2: Generic-accessible (GA) LMIC Weighted Average Regimen Price (USD, PPPY) .................................................... 7 Figure 3: HIV Resources in LMICs, 2000-2018 .....................................................................................................................................
    [Show full text]
  • 207931Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 207931Orig1s000 OTHER REVIEW(S) MEMORANDUM REVIEW OF REVISED LABEL AND LABELING Division of Medication Error Prevention and Analysis (DMEPA) Office of Medication Error Prevention and Risk Management (OMEPRM) Office of Surveillance and Epidemiology (OSE) Center for Drug Evaluation and Research (CDER) Date of This Memorandum: July 22, 2015 Requesting Office or Division: Division of Antiviral Products (DAVP) Application Type and Number: NDA 207931 Product Name and Strength: Technivie (ombitasvir, paritaprevir, ritonavir) Tablets, 12.5 mg/75 mg/50 mg Submission Date: June 19, 2015 and July 2, 2015 Applicant/Sponsor Name: Abbvie OSE RCM #: 2015-497-1 DMEPA Primary Reviewer: Mónica Calderón, PharmD, BCPS DMEPA Team Leader: Vicky Borders-Hemphill, PharmD 1 PURPOSE OF MEMO Abbvie has submitted the revised container label and carton labeling (Appendix A) for Technivie in response to recommendations we made during a previous label and labeling review. 1 Abbvie also submitted a response on June 19, 2015 to fulfill our request for the lot number and expiration date to be placed on the immediate container. Thus, the Division of Antiviral Products (DAVP) requested that we review the revised label and labeling to determine if it is acceptable from a medication error perspective. 2 CONCLUSIONS The revised container label and carton labeling is acceptable from a medication error perspective. The lot number and expiration date are printed on-line (i.e. as the product is 1 Calderon M. Label and Labeling Review for PRODUCT NAME (NDA 207931). Silver Spring (MD): Food and Drug Administration, Center for Drug Evaluation and Research, Office of Surveillance and Epidemiology, Division of Medication Error Prevention and Analysis (US); 2015 05 19.
    [Show full text]
  • FDA Fast Track and Priority Review Programs
    Order Code RS22814 February 21, 2008 FDA Fast Track and Priority Review Programs Susan Thaul Specialist in Drug Safety and Effectiveness Domestic Social Policy Division Summary By statutory requirements and by regulation, guidance, and practice, the Food and Drug Administration (FDA) works with several overlapping yet distinct programs to get to market quickly new drug and biological products that address unmet needs. FDA most frequently uses three mechanisms for that purpose: Accelerated Approval, Fast Track, and Priority Review. The first two affect the development process before a sponsor submits a marketing application. Accelerated Approval allows surrogate endpoints in trials to demonstrate effectiveness and is relevant in fewer situations than the others. The Fast Track program encourages a sponsor to consult with FDA while developing a product. Unlike the others, Priority Review involves no discussions of study design or procedure; it relates only to an application’s place in the review queue. Analysis of total approval time for approved applications under the Fast Track and Priority Review programs shows that for seven of the past nine years, Fast Track products have shorter median approval times than do all those applications assigned to Priority Review. It takes an average of 15 years from the moment a manufacturer first approaches the Food and Drug Administration (FDA) with an idea for a new drug to its final approval for marketing.1 Steps in the development and approval of a drug or biologic (e.g., a vaccine) involve actions by both the manufacturer and FDA. First, a manufacturer (sometimes referred to as the sponsor) submits to FDA an Investigational New Drug (IND) application for permission to conduct clinical studies in humans.
    [Show full text]
  • FDA Approves Lilly's LARTRUVO™ (Olaratumab) in Combination with Doxorubicin for Soft Tissue Sarcoma
    October 19, 2016 FDA Approves Lilly's LARTRUVO™ (olaratumab) in Combination with Doxorubicin for Soft Tissue Sarcoma -- LARTRUVO, in combination with doxorubicin, is the first FDA-approved front-line therapy for soft tissue sarcoma in four decades -- The approval was based on results from the positive Phase 2 JGDG trial -- LARTRUVO received the FDA's Breakthrough Therapy Designation and was approved under the Agency's Accelerated Approval program INDIANAPOLIS, Oct. 19, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has granted approval of LARTRUVO™ (olaratumab injection, 10 mg/mL), in combination with doxorubicin, for the treatment of adults with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline- containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery. LARTRUVO's indication is approved under Accelerated Approval, and is based on data from the Phase 2 portion of the pivotal JGDG trial. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. LARTRUVO, in combination with doxorubicin, is the first FDA-approved front-line therapy for STS in four decades. The confirmatory Phase 3 trial, ANNOUNCE, is fully enrolled. "LARTRUVO represents an important step forward in soft tissue sarcoma treatment," said William D. Tap, M.D., chief of the sarcoma medical oncology services at Memorial Sloan Kettering Cancer Center in New York and the principal investigator of the JGDG registration trial. "We are pleased with this approval, which will provide patients with a treatment option that offers new hope in their battle against this difficult disease." Soft tissue sarcoma is a complex disease with multiple subtypes, making it hard to diagnose and difficult to treat.
    [Show full text]
  • Download FDA's Expedited Drug Approval Programs
    Expedited Drug Approval Programs The process for collecting evidence in support of a new drug approval involves multiple steps. Drug developers (sponsors) collect evidence during pre-clinical and clinical phases of the process and submit it to the U.S. Food and Drug Administration (FDA) for evaluation of the drug’s safety and efficacy. The next step is a final review for marketing authorization which occurs when a drug sponsor submits a New Drug Application (NDA) to FDA for small molecule drugs or a Biologics Licensing Application (BLA) for biologics. FDA follows a standard review process – which typically takes up to 10 months – to determine whether to approve the drug. Throughout this process, from drug development to post- market monitoring, there are various points in which drug sponsors and FDA interact and exchange information. The time it takes for drug development and approval varies by drug and therapeutic area and FDA review is only part of this process. In most cases, most of this time is spent by drug sponsors in the data collection phases, e.g. clinical trials. But not all approvals follow the standard review process. Drug therapies that address unmet medical needs, treat serious or life-threatening conditions, or show a significant advantage over current therapies may be eligible for one or more of FDA’s four Expedited Review Programs. These programs are designed to accelerate the approval process and make the therapies available to patients quicker if it is determined the therapies’ benefits justify their risks.1 The four Expedited Review Programs are Priority Review, Accelerated Approval, Fast Track, and Breakthrough Therapy.
    [Show full text]
  • FDA Fast Track and Priority Review Programs
    FDA Fast Track and Priority Review Programs February 21, 2008 Congressional Research Service https://crsreports.congress.gov RS22814 FDA Fast Track and Priority Review Programs Summary By statutory requirements and by regulation, guidance, and practice, the Food and Drug Administration (FDA) works with several overlapping yet distinct programs to get to market quickly new drug and biological products that address unmet needs. FDA most frequently uses three mechanisms for that purpose: Accelerated Approval, Fast Track, and Priority Review. The first two affect the development process before a sponsor submits a marketing application. Accelerated Approval allows surrogate endpoints in trials to demonstrate effectiveness and is relevant in fewer situations than the others. The Fast Track program encourages a sponsor to consult with FDA while developing a product. Unlike the others, Priority Review involves no discussions of study design or procedure; it relates only to an application’s place in the review queue. Analysis of total approval time for approved applications under the Fast Track and Priority Review programs shows that for seven of the past nine years, Fast Track products have shorter median approval times than do all those applications assigned to Priority Review. Congressional Research Service FDA Fast Track and Priority Review Programs Contents Mechanisms to Expedite the Development and Review Process .................................................... 1 Accelerated Approval ...............................................................................................................
    [Show full text]
  • JULY 2019 Mrx Pipeline a View Into Upcoming Specialty and Traditional Drugs TABLE of CONTENTS
    JULY 2019 MRx Pipeline A view into upcoming specialty and traditional drugs TABLE OF CONTENTS EDITORIAL STAFF Introduction Maryam Tabatabai, PharmD Editor in Chief Senior Director, Drug Information Pipeline Deep Dive Carole Kerzic, RPh Executive Editor Drug Information Pharmacist Keep on Your Radar Consultant Panel Michelle Booth, Pharm D Director, Medical Pharmacy Strategy Becky Borgert, PharmD, BCOP Pipeline Drug List Director, Clinical Oncology Product Development Lara Frick, PharmD, BCPS, BCPP Drug Information Pharmacist Glossary Robert Greer, RPh, BCOP Senior Director, Clinical Strategy and Programs YuQian Liu, PharmD Manager, Specialty Clinical Programs Troy Phelps Senior Director, Analytics Nothing herein is or shall be construed as a promise or representation regarding past or future events and Magellan Rx Management expressly disclaims any and all liability relating to the use of or reliance on the information contained in this presentation. The information contained in this publication is intended for educational purposes only and should not be considered clinical, financial, or legal advice. By receipt of this publication, each recipient agrees that the information contained herein will be kept confidential and that the information will not be photocopied, reproduced, distributed to, or disclosed to others at any time without the prior written consent of Magellan Rx Management. 1 | magellanrx.com INTRODUCTION Welcome to the MRx Pipeline. In its third year of publication, this quarterly report offers clinical insights and competitive intelligence on anticipated drugs in development. Our universal forecast addresses trends applicable across market segments. Traditional and specialty drugs, agents under the pharmacy and medical benefits, new molecular entities, pertinent new and expanded indications for existing medications, and biosimilars are profiled in the report.
    [Show full text]
  • Accelerated Approval for Soft Tissue Sarcoma Treatment
    Accelerated Approval for Soft Tissue Sarcoma Treatment he FDA granted accelerated ap- effects of treatment with olaratumab tion, breakthrough therapy designation, proval program, which allows approval proval to olaratumab (Lartruvo) are nausea, fatigue, neutropenia, mus- and priority review status because pre- of a drug to treat a serious or life- Twith doxorubicin to treat adults with culoskeletal pain, mucositis, alopecia, liminary clinical evidence indicated it threatening disease or condition based certain types of soft tissue sarcoma (STS). vomiting, diarrhea, decreased appe- may offer a substantial improvement on clinical data showing the drug has Olaratumab is approved for use with tite, abdominal pain, neuropathy, and in effectiveness in the treatment of a an effect on a surrogate endpoint that is the FDA-approved chemotherapy drug headache. serious or life-threatening disease or reasonably likely to predict clinical ben- doxorubicin for the treatment of patients The FDA granted the olara- condition. The FDA is approving the efit. Olaratumab also received orphan with STS who cannot be cured with ra- tumab application fast track designa- drug under the agency’s accelerated ap- drug designation. OT diation or surgery and who have a type of STS for which an anthracycline is an appropriate treatment. “For these patients, Lartruvo, added to doxorubicin, provides a new treat- ment option,” said Richard Pazdur, MD, Director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research and Acting Director of the FDA’s Oncology Center of Excellence. “This is the first new therapy approved by the FDA for the initial treat- ment of soft tissue sarcoma since doxoru- bicin’s approval more than 40 years ago.” The NCI estimates that 12,310 new cases of STS and nearly 5,000 deaths are likely to occur from the disease in 2016.
    [Show full text]
  • Overview of U.S. FDA Center for Biologics Evaluation and Research
    Overview of U.S. FDA Center for Biologics Evaluation and Research David Martin, M.D., M.P.H. Director, Division of Epidemiology Center for Biologics Evaluation and Research US Food and Drug Administration Application of Pharmacovigilance to U.S. FDA Regulatory Decisions for Vaccines June 2, 2012 Outline . FDA: a regulatory agency granted the authority to ensure that U.S. licensed vaccines are safe and effective . Structure of FDA and the Center for Biologics Evaluation and Research . Historical timeline of the expansion of vaccine regulation in the United States (optional topic) 2 FDA Legal Framework Statutes (enacted by Congress, signed by President) Regulations (FDA) 3 Main Statutes Pertinent to Vaccine Safety . Federal Food, Drug and Cosmetic Act . Amended by the Food and Drug Administration Amendments Act of 2007 . Public Health Service Act . National Childhood Vaccine Injury Act 4 US Code of Federal Regulations (CFR) FDA implements statutes through regulations • 21 CFR 600-680 Biological Product Standards • 21 CFR 314.126 Adequate and well-controlled trials • 21 CFR 312 Investigational New Drug Application • 21 CFR 210-211 Good Manufacturing Practices • 21 CFR 58 Good Laboratory Practices • 21 CFR 56 Institutional Review Boards • 21 CFR 50 Protection of Human Subjects 5 National Childhood Vaccine Injury Act . Designed to stabilize supply and cost of vaccines by addressing liability . Created a “no fault” compensation system . The vaccine injury table lists conditions presumed to be caused by vaccines within specific timeframes . Financed through excise tax on recommended vaccine products . Created additional U.S. vaccine safety infrastructure . National Vaccine Program Office to coordinate HRSA, CDC, FDA, NIH .
    [Show full text]
  • Inhaled Antimicrobial Therapy – Barriers to Effective Treatment☆
    Advanced Drug Delivery Reviews 85 (2015) 24–43 Contents lists available at ScienceDirect Advanced Drug Delivery Reviews journal homepage: www.elsevier.com/locate/addr Inhaled antimicrobial therapy – Barriers to effective treatment☆ Jeffry Weers Novartis Pharmaceuticals Corporation, 150 Industrial Road, San Carlos, CA, USA article info abstract Available online 1 September 2014 Inhaled antibiotics dramatically improve targeting of drug to the site of respiratory infections, while simulta- neously minimizing systemic exposure and associated toxicity. The high local concentrations of antibiotic may Keywords: enable more effective treatment of multi-drug resistant pathogens. This review explores barriers to effective Biofilm treatment with inhaled antibiotics. In addition, potential opportunities for improvements in treatment are Dry powder inhaler reviewed. Endpoint © 2014 Elsevier B.V. All rights reserved. Fixed dose combination Nebulizer Partial liquid ventilation Tolerability Contents 1. Introduction...............................................................25 1.1. Chronic infections in cystic fibrosis(CF)...............................................25 1.2. Chronicinfectionsinnon-CFbronchiectasis(NCFBE)..........................................26 1.3. Acuteexacerbationsinchronicobstructivepulmonarydisease(AECOPD)................................26 1.4. Ventilator-associatedpneumonia(VAP)...............................................27 1.5. Otherinfections..........................................................27 1.6. Barrierstodevelopmentofinhaledantibiotics............................................27
    [Show full text]
  • 2021 PPO Annual Notice of Change (PDF)
    Aetna MedicareSM Plan (PPO) offered by Aetna Life Insurance Company Annual Notice of Changes for 2021 You are currently enrolled as a member of Aetna Medicare Plan (PPO). Next year, there will be some changes to the plan’s costs and benefits. This booklet tells about the changes. What to do now 1. ASK: Which changes apply to you £ Check the changes to our benefits and costs to see if they affect you. • It’s important to review your coverage now to make sure it will meet your needs next year. • Do the changes affect the services you use? • Look in Sections 1.5 and 1.6 for information about benefit and cost changes for our plan. £ Check the changes in the booklet to our prescription drug coverage to see if they affect you. • Will your drugs be covered? • Are your drugs in a different tier, with different cost sharing? • Do any of your drugs have new restrictions, such as needing approval from us before you fill your prescription? • Can you keep using the same pharmacies? Are there changes to the cost of using this pharmacy? • Review the 2021 Drug List and look in Section 1.6 for information about changes to our drug coverage. • Your drug costs may have risen since last year. Talk to your doctor about lower cost alternatives that may be available for you; this may save you in annual out-of-pocket costs throughout the year. To get additional information on drug prices visit go.medicare.gov/drugprices. These dashboards highlight which manufacturers have been increasing their prices and also show other year-to-year drug price information.
    [Show full text]
  • House Bill No. 1910
    SECOND REGULAR SESSION HOUSE BILL NO. 1910 100TH GENERAL ASSEMBLY INTRODUCED BY REPRESENTATIVE CLEMENS. 4352H.01I DANA RADEMAN MILLER, Chief Clerk AN ACT To amend chapter 376, RSMo, by adding thereto nine new sections relating to prescription drug costs. Be it enacted by the General Assembly of the state of Missouri, as follows: Section A. Chapter 376, RSMo, is amended by adding thereto nine new sections, to be 2 known as sections 376.2060, 376.2061, 376.2062, 376.2064, 376.2066, 376.2068, 376.2070, 3 376.2072, and 376.2073, to read as follows: 376.2060. As used in sections 376.2060 to 376.2070, unless otherwise clearly 2 indicated by context, the following terms mean: 3 (1) "Closed meeting", as defined under section 610.010; 4 (2) "Commission", the drug cost review commission established under section 5 376.2061; 6 (3) "Department", the department of commerce and insurance; 7 (4) "Director", the director of the department; 8 (5) "Drug", as defined under section 376.1350; 9 (6) "Enrollee", as defined under section 376.1350; 10 (7) "Health benefit plan", as defined under section 376.1350; however, for purposes 11 of sections 376.2060 to 376.2070, the term "health benefit plan" shall be limited to plans 12 providing coverage for outpatient prescription drugs; 13 (8) "Health carrier", as defined under section 376.1350; 14 (9) "Person", an individual, corporation, partnership, limited liability company, 15 association, joint stock company, business trust, unincorporated organization, or other 16 legal entity; EXPLANATION — Matter enclosed in bold-faced brackets [thus] in the above bill is not enacted and is intended to be omitted from the law.
    [Show full text]